AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients
Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.
Source: medscape.com